Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for Dianthus Therapeutics (DNTH) over the last 6 years, with Q3 2025 value amounting to $78.6 million.

  • Dianthus Therapeutics' Change in Acquisitions & Divestments rose 31353.16% to $78.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $305.3 million, marking a year-over-year increase of 40886.17%. This contributed to the annual value of $127.0 million for FY2024, which is 6327.06% up from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' Change in Acquisitions & Divestments is $78.6 million, which was up 31353.16% from $59.6 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Change in Acquisitions & Divestments registered a high of $85.0 million during Q4 2024, and its lowest value of $2.0 million during Q4 2022.
  • Moreover, its 4-year median value for Change in Acquisitions & Divestments was $20.4 million (2023), whereas its average is $35.6 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first surged by 80000.0% in 2023, then plummeted by 6344.53% in 2024.
  • Dianthus Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $2.0 million in 2022, then skyrocketed by 800.0% to $18.0 million in 2023, then surged by 372.22% to $85.0 million in 2024, then fell by 7.56% to $78.6 million in 2025.
  • Its Change in Acquisitions & Divestments was $78.6 million in Q3 2025, compared to $59.6 million in Q2 2025 and $82.1 million in Q1 2025.